ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia

Epigenetics

Volumn 7, Issue 5, 2012, Pages 464-472

  Guay, Simon Pierre ^a,b   Brisson, Diane ^b   Munger, Johannie ^a,b   Lamarche, Benoit ^c   Gaudet, Daniel ^b,d   Bouchard, Luigi ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CHICOUTIMI HOSPITAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

ABCA1; Coronary artery disease; DNA methylation; Familial hypercholesterolemia; HDL cholesterol

Indexed keywords

ABC TRANSPORTER A1; ANTILIPEMIC AGENT; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DNA METHYLATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PHOSPHOLIPID BLOOD LEVEL; PROMOTER REGION;

EID: 84860596947     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.19633     Document Type: Article

References (48)

1. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. FASEB J 2008; 22:4044-54; PMID:18716026; http://dx.doi.org/10.1096/fj.08-117150.
2. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67:1185-9; PMID:2035438; http://dx.doi.org/10.1016/0002-9149(91)90924-A.
3. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Triglycerides and HDLcholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. Atherosclerosis 1996; 119:235-45; PMID:8808500; http://dx.doi.org/10.1016/0021-9150(95)05653-X.
4. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009; 50:189-94; PMID:19064999; http://dx.doi.org/10.1194/jlr.R800088-JLR200.
5. Heller DA, de Faire U, Pedersen NL, Dahlén G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993; 328:1150-6; PMID:8455681; http://dx.doi.org/10.1056/NEJM199304223281603.
6. van Aalst-Cohen ES, Jansen AC, Boekholdt SM, Tanck MW, Fontecha MR, Cheng S, et al. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur J Hum Genet 2005; 13:1137-42; PMID:16030523; http://dx.doi.org/10.1038/sj.ejhg.5201467.
7. Ma XY, Liu JP, Song ZY. Associations of the ATPbinding cassette transporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk: a meta-analysis. Atherosclerosis 2011; 215:428-34; PMID:21310416; http://dx.doi.org/10.1016/j.atherosclerosis.2011.01.008.
8. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 2010; 51:2032-57; PMID:20421590; http://dx.doi.org/10.1194/jlr.R004739.
9. Joyce C, Freeman L, Brewer HB Jr, Santamarina-Fojo S. Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol 2003; 23:965-71; PMID:12615681; http://dx.doi.org/10.1161/01.ATV.0000055194.85073.FF.
10. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest 1995; 96:78-87; PMID:7615839; http://dx.doi.org/10.1172/JCI118082.
11. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107:85-98; PMID:7945562; http://dx.doi.org/10.1016/0021-9150(94)90144-9.
12. Tobi EW, Lumey LH, Talens RP, Kremer D, Putter H, Stein AD, et al. DNA methylation differences after exposure to prenatal famine are common and timingand sex-specific. Hum Mol Genet 2009; 18:4046-53; PMID:19656776; http://dx.doi.org/10.1093/hmg/ddp353.
13. Talens RP, Boomsma DI, Tobi EW, Kremer D, Jukema JW, Willemsen G, et al. Variation, patterns and temporal stability of DNA methylation: considerations for epigenetic epidemiology. FASEB J 2010; 24:3135-44; PMID:20385621; http://dx.doi.org/10.1096/fj.09-150490.
14. Henikoff S, Matzke MA. Exploring and explaining epigenetic effects. Trends Genet 1997; 13:293-5; PMID:9260513; http://dx.doi.org/10.1016/S0168-9525(97)01219-5.
15. Turcot V, Bouchard L, Faucher G, Tchernof A, Deshaies Y, Pérusse L, et al. DPP4 gene DNA methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity (Silver Spring) 2011; 19:388-95; PMID:20847730; http://dx.doi.org/10.1038/oby.2010.198.
16. Bouchard L, Thibault S, Guay SP, Santure M, Monpetit A, St-Pierre J, et al. Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy. Diabetes Care 2010; 33:2436-41; PMID:20724651; http://dx.doi.org/10.2337/dc10-1024.
17. Zhang X, Wu M, Xiao H, Lee MT, Levin L, Leung YK, et al. Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer. Prostate 2010; 70:765-76; PMID:20054818.
18. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16:6-21; PMID:11782440; http://dx.doi.org/10.1101/gad.947102.
19. Defesche J. World health organisation report on familial hypercholesterolemia. Atherosclerosis 2001; 154:242; PMID:11137105; http://dx.doi.org/10.1016/S0021-9150(00)00646-8.
20. Vohl MC, Moorjani S, Roy M, Gaudet D, Torres AL, Minnich A, et al. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin Genet 1997; 52:1-6; PMID:9272705; http://dx.doi.org/10.1111/j.1399-0004.1997.tb02506.x.
21. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394-8; PMID:11326085; http://dx.doi.org/10.1126/science.1060458.
22. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338:92; PMID:19221140; http://dx.doi.org/10.1136/bmj.b92.
23. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4:214-25; PMID:17380167; http://dx.doi.org/10.1038/ncpcardio0836.
24. Hegele RA. Environmental modulation of atherosclerosis end points in familial hypercholesterolemia. Atheroscler Suppl 2002; 2:5-7; PMID:11923122; http://dx.doi.org/10.1016/S1567-5688(01)00013-7.
25. Hogue JC, Lamarche B, Gaudet D, Tremblay AJ, Després JP, Bergeron J, et al. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis 2007; 190:429-35; PMID:16546193; http://dx.doi.org/10.1016/j.atherosclerosis.2006.02.023.
26. van der Graaf A, Vissers MN, Gaudet D, Brisson D, Sivapalaratnam S, Roseboom TJ, et al. Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring. Arterioscler Thromb Vasc Biol 2010; 30:2673-7; PMID:20864670; http://dx.doi.org/10.1161/ATVBAHA.110.209064.
27. Remaley AT, Schumacher UK, Stonik JA, Farsi BD, Nazih H, Brewer HB Jr. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Vasc Biol 1997; 17:1813-1821; PMID:9327782; http://dx.doi.org/10.1161/01.ATV.17.9.1813.
28. Santamarina-Fojo S, Peterson K, Knapper C, Qiu Y, Freeman L, Cheng JF, et al. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci USA 2000; 97:7987-92; PMID:10884428; http://dx.doi.org/10.1073/pnas.97.14.7987.
29. Langmann T, Porsch-Ozcürümez M, Heimerl S, Probst M, Moehle C, Taher M, et al. Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter: role of Sp1/3, E-box binding factors and an oncostatin M-responsive element. J Biol Chem 2002; 277:14443-50; PMID:11839742; http://dx.doi.org/10.1074/jbc.M110270200.
30. Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W, et al. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 2004; 175:269-79; PMID:15262183; http://dx.doi.org/10.1016/j.atherosclerosis.2004.02.019.
31. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21:2933-42; PMID:15860560; http://dx.doi.org/10.1093/bioinformatics/bti473.
32. Le Goff W, Zheng P, Brubaker G, Smith JD. Identification of the cAMP-responsive enhancer of the murine ABCA1 gene: requirement for CREB1 and STAT3/4 elements. Arterioscler Thromb Vasc Biol 2006; 26:527-33; PMID:16373613; http://dx.doi.org/10.1161/01.ATV.0000201042.00725.84.
33. Wang XQ, Panousis CG, Alfaro ML, Evans GF, Zuckerman SH. Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. Arterioscler Thromb Vasc Biol 2002; 22:5-9; PMID:12006410; http://dx.doi.org/10.1161/01.ATV.0000018287.03856.DD.
34. Gaudet D, Tremblay G, Perron P, Gagné C, Ouadahi Y, Moorjani S. Familial hypercholesterolemia in eastern Quebec: a public health problem? The experience of the hyperlipidemia clinic of Chicoutimi. Union Med Can 1995; 124:54-60; PMID:8846258.
35. Gaudet D, Gagné C, Perron P, Couture P, Tonstad S. Ethical issues in molecular screening for heterozygous familial hypercholesterolemia: the complexity of dealing with genetic susceptibility to coronary artery disease. Community Genet 1999; 2:2-8; PMID:11658106; http://dx.doi.org/10.1159/000016176.
36. Bertolini S, Pisciotta L, Di Scala L, Langheim S, Bellocchio A, Masturzo P, et al. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 2004; 174:57-65; PMID:15135251; http://dx.doi.org/10.1016/j.atherosclerosis.2003.12.037.
37. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2,400 patients. J Intern Med 2004; 256:482-90; PMID:15554949; http://dx.doi.org/10.1111/j.1365-2796.2004.01405.x.
38. Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2005; 25:1475-81; PMID:15879303; http://dx.doi.org/10.1161/01.ATV.0000168909.44877.a7.
39. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209:189-94; PMID:19818960; http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.014.
40. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011; 60:1544-53; PMID:21551187; http://dx.doi.org/10.1136/gut.2011.237495.
41. Gaudet D, Vohl MC, Julien P, Tremblay G, Perron P, Gagné C, et al. Relative contribution of lowdensity lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. Am J Cardiol 1998; 82:299-305; PMID:9708657; http://dx.doi.org/10.1016/S0002-9149(98)00328-2.
42. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53; PMID:9686693; http://dx.doi.org/10.1002/(SICI)1096-9136(199807)15:7539::AID-DIA6683.0.CO;2-S.
43. Standardization of anthropometric measurements. In: Lohman T, Roche A, Martorel R, Editors. The Airlie (VA) consensus conference. Champaigh, IL: Human Kinetics 1988; 39-80.
44. Gaudet D, Arsenault S, Bélanger C, Hudson T, Perron P, Bernard M, et al. Procedure to protect confidentiality of familial data in community genetics and genomic research. Clin Genet 1999; 55:259-64; PMID:10361987; http://dx.doi.org/10.1034/j.1399-0004.1999.550408.x.
45. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502; PMID:4337382.
46. Moorjani S, Dupont A, Labrie F, Lupien PJ, Brun D, Gagné C, et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987; 36:244-50; PMID:3102895; http://dx.doi.org/10.1016/0026-0495(87)90183-1.
47. Pérusse M, Pascot A, Després JP, Couillard C, Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001; 42:1331-4; PMID:11483636.
48. Albrecht C, Simon-Vermot I, Elliott JI, Higgins CF, Johnston DG, Valabhji J. Leukocyte ABCA1 gene expression is associated with fasting glucose concentration in normoglycemic men. Metabolism 2004; 53:17-21; PMID:14681836; http://dx.doi.org/10.1016/j.metabol.2003.07.009.